Articles

A Randomized, Phase 2 Trial Evaluating Atezolizumab Maintenance Therapy Following Chemoradiotherapy in LS-SCLC

The DeLLphi-304 trial shows tarlatamab significantly improves survival with a manageable adverse-event profile over chemotherapy, establishing a new standard of care for patients with small cell lung cancer (SCLC) after platinum-based chemotherapy. Read More ›

IMforte Phase 3 Study: Lurbinectedin Plus Atezolizumab Improves Survival in Extensive-Stage Small Cell Lung Cancer

A randomized, phase 2 study found atezolizumab maintenance after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC) did not improve survival outcomes and caused additional toxicities. Read More ›

Promising Phase 2 Results for ZG006, a Trispecific T-Cell Engager, in Advanced Small Cell Lung Cancer

The IMforte study showed clinically meaningful improvements in progression-free survival and overall survival with lurbinectedin plus atezolizumab compared with atezolizumab alone in patients with extensive-stage small cell lung cancer. Read More ›

ZG006 demonstrated promising efficacy and a tolerable safety profile in patients with advanced small cell lung cancer, supporting further evaluation in the ongoing phase 2 study. Read More ›

Understanding the Current Paradigm and New Approaches in the Care of Patients With Endometrial Cancer

In this fourth installment, Paula reviews relevant data for immunotherapies currently FDA approved for patients with advanced endometrial cancer. Read More ›

Advancing Nursing Science Through Data Science

In this third installment, Paula will discuss the importance and relevance of data science in advancing the field of nursing. Read More ›

Treatment of Patients With Advanced Endometrial Carcinoma

In this first installment, Paula will discuss recent data of immunotherapy in patients with advanced endometrial cancer and highlight nursing considerations to help manage side effects. Read More ›

Importance of Health Equity in Gynecologic Cancers

In this second installment, Paula will discuss a health equity study investigating the association of neighborhood socioeconomic deprivation in patients with gynecologic cancers. Read More ›

SIM0270 Monotherapy and in Combination With Everolimus Shows Promise in Advanced Breast Cancer Treatment

By Erica L. Mayer, MD, MPH

SABCS 2024 - Breast Cancer Faculty Commentary

Dr Erica Mayer explains the results of a study utilizing the novel SERD SIM0270, as monotherapy and in combination, in the treatment of patients with estrogen receptor–positive, HER2-negative advanced breast cancer. Read More ›